| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 94 | 2026 | 677 | 13.830 |
Why?
|
| Diabetes Mellitus | 90 | 2023 | 445 | 10.710 |
Why?
|
| Hypoglycemia | 23 | 2026 | 48 | 6.830 |
Why?
|
| Hypoglycemic Agents | 45 | 2026 | 247 | 6.640 |
Why?
|
| Medication Adherence | 25 | 2020 | 235 | 5.090 |
Why?
|
| Blood Glucose | 43 | 2026 | 315 | 4.300 |
Why?
|
| Middle Aged | 166 | 2026 | 7515 | 3.710 |
Why?
|
| Humans | 238 | 2026 | 16832 | 3.710 |
Why?
|
| Male | 185 | 2026 | 9556 | 3.690 |
Why?
|
| Blood Glucose Self-Monitoring | 16 | 2021 | 37 | 3.510 |
Why?
|
| Aged | 140 | 2026 | 5901 | 3.470 |
Why?
|
| Female | 189 | 2026 | 12193 | 3.360 |
Why?
|
| Glycated Hemoglobin A | 36 | 2021 | 176 | 3.150 |
Why?
|
| California | 78 | 2026 | 2244 | 2.790 |
Why?
|
| Diabetes Mellitus, Type 1 | 16 | 2022 | 116 | 2.730 |
Why?
|
| Physician-Patient Relations | 11 | 2020 | 169 | 2.710 |
Why?
|
| Health Literacy | 10 | 2021 | 39 | 2.710 |
Why?
|
| Residence Characteristics | 9 | 2017 | 244 | 2.250 |
Why?
|
| Adult | 103 | 2025 | 7255 | 2.210 |
Why?
|
| Communication Barriers | 8 | 2017 | 29 | 2.030 |
Why?
|
| Ethnic Groups | 24 | 2016 | 418 | 1.900 |
Why?
|
| Cardiovascular Diseases | 20 | 2025 | 520 | 1.890 |
Why?
|
| Aging | 12 | 2019 | 146 | 1.840 |
Why?
|
| Socioeconomic Factors | 31 | 2017 | 571 | 1.770 |
Why?
|
| Diabetes Complications | 17 | 2020 | 93 | 1.690 |
Why?
|
| Food Supply | 5 | 2018 | 41 | 1.670 |
Why?
|
| Cohort Studies | 42 | 2026 | 2396 | 1.590 |
Why?
|
| Insulin | 20 | 2025 | 181 | 1.580 |
Why?
|
| Electronic Health Records | 10 | 2020 | 702 | 1.560 |
Why?
|
| Body Mass Index | 17 | 2017 | 925 | 1.470 |
Why?
|
| Hospitalization | 9 | 2024 | 816 | 1.450 |
Why?
|
| Managed Care Programs | 22 | 2017 | 275 | 1.440 |
Why?
|
| Dyslipidemias | 3 | 2019 | 57 | 1.390 |
Why?
|
| Delivery of Health Care, Integrated | 11 | 2017 | 515 | 1.380 |
Why?
|
| Insulin Resistance | 23 | 2016 | 127 | 1.380 |
Why?
|
| Risk Factors | 60 | 2025 | 3108 | 1.380 |
Why?
|
| Pharmaceutical Services | 6 | 2019 | 37 | 1.370 |
Why?
|
| Hispanic Americans | 20 | 2017 | 350 | 1.350 |
Why?
|
| Risk Assessment | 18 | 2023 | 1047 | 1.340 |
Why?
|
| Population Surveillance | 5 | 2018 | 242 | 1.330 |
Why?
|
| Dementia | 9 | 2025 | 137 | 1.260 |
Why?
|
| Aged, 80 and over | 34 | 2026 | 1887 | 1.260 |
Why?
|
| United States | 52 | 2026 | 3858 | 1.220 |
Why?
|
| Retrospective Studies | 26 | 2026 | 2463 | 1.200 |
Why?
|
| European Continental Ancestry Group | 20 | 2017 | 400 | 1.170 |
Why?
|
| Insurance, Health | 9 | 2017 | 167 | 1.150 |
Why?
|
| Depression | 13 | 2017 | 479 | 1.140 |
Why?
|
| Health Status Disparities | 5 | 2017 | 145 | 1.120 |
Why?
|
| Postal Service | 7 | 2020 | 72 | 1.090 |
Why?
|
| Communication | 6 | 2020 | 183 | 1.060 |
Why?
|
| Patient Compliance | 9 | 2011 | 262 | 1.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 155 | 1.040 |
Why?
|
| Health Expenditures | 3 | 2017 | 69 | 1.020 |
Why?
|
| Culturally Competent Care | 2 | 2017 | 10 | 1.010 |
Why?
|
| Continental Population Groups | 16 | 2016 | 255 | 1.010 |
Why?
|
| Cross-Sectional Studies | 35 | 2017 | 1233 | 1.000 |
Why?
|
| Health Behavior | 13 | 2015 | 332 | 0.980 |
Why?
|
| Commerce | 2 | 2017 | 37 | 0.970 |
Why?
|
| Quality of Life | 6 | 2017 | 477 | 0.950 |
Why?
|
| Follow-Up Studies | 25 | 2018 | 1058 | 0.940 |
Why?
|
| Obesity | 14 | 2017 | 811 | 0.930 |
Why?
|
| Professional-Patient Relations | 5 | 2014 | 45 | 0.920 |
Why?
|
| Prescription Drugs | 3 | 2017 | 29 | 0.910 |
Why?
|
| Glycemic Index | 5 | 2010 | 17 | 0.910 |
Why?
|
| Language | 7 | 2016 | 51 | 0.890 |
Why?
|
| Diabetic Angiopathies | 11 | 2015 | 33 | 0.890 |
Why?
|
| Coronary Disease | 2 | 2016 | 125 | 0.880 |
Why?
|
| Electronic Prescribing | 3 | 2015 | 7 | 0.860 |
Why?
|
| Patient Acceptance of Health Care | 6 | 2018 | 353 | 0.860 |
Why?
|
| Self Care | 9 | 2014 | 139 | 0.840 |
Why?
|
| Atherosclerosis | 4 | 2021 | 51 | 0.830 |
Why?
|
| Registries | 20 | 2020 | 449 | 0.830 |
Why?
|
| Trust | 3 | 2014 | 33 | 0.820 |
Why?
|
| Drug Utilization | 5 | 2016 | 112 | 0.800 |
Why?
|
| Emergency Service, Hospital | 5 | 2018 | 393 | 0.800 |
Why?
|
| Prospective Studies | 18 | 2020 | 1186 | 0.790 |
Why?
|
| Cost Sharing | 3 | 2017 | 28 | 0.790 |
Why?
|
| Glucose | 1 | 2023 | 29 | 0.790 |
Why?
|
| Tool Use Behavior | 1 | 2023 | 2 | 0.770 |
Why?
|
| Arteriosclerosis | 11 | 2005 | 15 | 0.770 |
Why?
|
| Health Maintenance Organizations | 8 | 2010 | 358 | 0.750 |
Why?
|
| African Americans | 13 | 2017 | 394 | 0.740 |
Why?
|
| Educational Status | 12 | 2014 | 163 | 0.740 |
Why?
|
| Antidepressive Agents | 2 | 2014 | 140 | 0.740 |
Why?
|
| Cholesterol, LDL | 8 | 2016 | 113 | 0.730 |
Why?
|
| Treatment Outcome | 11 | 2021 | 1098 | 0.720 |
Why?
|
| Biosensing Techniques | 1 | 2021 | 3 | 0.680 |
Why?
|
| Incidence | 20 | 2017 | 1229 | 0.680 |
Why?
|
| Deductibles and Coinsurance | 3 | 2017 | 31 | 0.670 |
Why?
|
| Diabetic Neuropathies | 2 | 2016 | 10 | 0.660 |
Why?
|
| Diabetic Nephropathies | 4 | 2015 | 24 | 0.650 |
Why?
|
| Patient Education as Topic | 3 | 2020 | 186 | 0.650 |
Why?
|
| Thiazolidinediones | 5 | 2010 | 41 | 0.650 |
Why?
|
| Housing | 3 | 2017 | 38 | 0.630 |
Why?
|
| Glomerular Filtration Rate | 3 | 2026 | 157 | 0.630 |
Why?
|
| Economic Recession | 2 | 2017 | 4 | 0.630 |
Why?
|
| Crime | 3 | 2016 | 18 | 0.620 |
Why?
|
| Data Accuracy | 2 | 2023 | 26 | 0.620 |
Why?
|
| Health Records, Personal | 3 | 2015 | 10 | 0.610 |
Why?
|
| Safety | 2 | 2016 | 43 | 0.600 |
Why?
|
| Self Report | 6 | 2020 | 248 | 0.590 |
Why?
|
| Insurance, Pharmaceutical Services | 3 | 2014 | 22 | 0.580 |
Why?
|
| Insulin Detemir | 1 | 2018 | 1 | 0.560 |
Why?
|
| Insulin, Isophane | 1 | 2018 | 2 | 0.560 |
Why?
|
| Insulin Glargine | 1 | 2018 | 6 | 0.560 |
Why?
|
| Stress, Psychological | 2 | 2016 | 136 | 0.550 |
Why?
|
| Appointments and Schedules | 2 | 2011 | 25 | 0.550 |
Why?
|
| Internet | 3 | 2017 | 207 | 0.550 |
Why?
|
| Kidney Failure, Chronic | 6 | 2011 | 144 | 0.530 |
Why?
|
| Environment | 2 | 2017 | 47 | 0.520 |
Why?
|
| Health Status | 4 | 2017 | 256 | 0.520 |
Why?
|
| African Continental Ancestry Group | 9 | 2016 | 117 | 0.520 |
Why?
|
| Emergency Medical Services | 1 | 2017 | 41 | 0.510 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2017 | 290 | 0.510 |
Why?
|
| Patient Handoff | 1 | 2017 | 2 | 0.510 |
Why?
|
| Primary Health Care | 5 | 2017 | 693 | 0.490 |
Why?
|
| Health Services Accessibility | 9 | 2017 | 262 | 0.490 |
Why?
|
| Social Support | 3 | 2014 | 195 | 0.490 |
Why?
|
| Cities | 1 | 2016 | 28 | 0.490 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 21 | 0.490 |
Why?
|
| Smoking | 12 | 2021 | 373 | 0.480 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 15 | 0.480 |
Why?
|
| Young Adult | 17 | 2020 | 2456 | 0.480 |
Why?
|
| Sulfonylurea Compounds | 5 | 2026 | 30 | 0.460 |
Why?
|
| Time Factors | 12 | 2021 | 989 | 0.460 |
Why?
|
| Algorithms | 3 | 2025 | 210 | 0.460 |
Why?
|
| Hypertriglyceridemia | 1 | 2015 | 12 | 0.460 |
Why?
|
| Age Factors | 8 | 2017 | 814 | 0.450 |
Why?
|
| Databases, Pharmaceutical | 1 | 2015 | 6 | 0.450 |
Why?
|
| Life Style | 3 | 2014 | 305 | 0.450 |
Why?
|
| Poverty Areas | 1 | 2015 | 23 | 0.440 |
Why?
|
| Coronary Artery Disease | 1 | 2015 | 79 | 0.440 |
Why?
|
| Longitudinal Studies | 14 | 2020 | 653 | 0.440 |
Why?
|
| Statistics as Topic | 1 | 2015 | 54 | 0.430 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2015 | 189 | 0.430 |
Why?
|
| Health Surveys | 10 | 2015 | 226 | 0.420 |
Why?
|
| Quality Improvement | 3 | 2025 | 184 | 0.420 |
Why?
|
| Fasting | 6 | 2016 | 45 | 0.410 |
Why?
|
| Glucose Intolerance | 10 | 2013 | 45 | 0.410 |
Why?
|
| Financing, Personal | 3 | 2017 | 18 | 0.400 |
Why?
|
| Outcome Assessment (Health Care) | 6 | 2012 | 199 | 0.400 |
Why?
|
| Decision Making | 2 | 2014 | 164 | 0.400 |
Why?
|
| Antihypertensive Agents | 7 | 2015 | 157 | 0.400 |
Why?
|
| Patient Access to Records | 1 | 2013 | 12 | 0.390 |
Why?
|
| Amputation | 2 | 2011 | 11 | 0.380 |
Why?
|
| Comorbidity | 15 | 2018 | 516 | 0.370 |
Why?
|
| Cognition | 4 | 2022 | 90 | 0.360 |
Why?
|
| Adolescent | 13 | 2017 | 3464 | 0.350 |
Why?
|
| Temperature | 2 | 2017 | 18 | 0.350 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 3 | 2026 | 14 | 0.340 |
Why?
|
| Heart Failure | 4 | 2015 | 403 | 0.340 |
Why?
|
| Comparative Effectiveness Research | 3 | 2026 | 60 | 0.340 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2011 | 12 | 0.340 |
Why?
|
| Multivariate Analysis | 9 | 2015 | 489 | 0.340 |
Why?
|
| Proportional Hazards Models | 9 | 2017 | 657 | 0.330 |
Why?
|
| Triglycerides | 2 | 2011 | 78 | 0.330 |
Why?
|
| Outcome and Process Assessment (Health Care) | 6 | 2010 | 85 | 0.330 |
Why?
|
| Body Constitution | 5 | 2005 | 35 | 0.320 |
Why?
|
| Myocardial Ischemia | 3 | 2004 | 21 | 0.320 |
Why?
|
| Dental Care for Chronically Ill | 1 | 2010 | 1 | 0.320 |
Why?
|
| Chronic Disease | 3 | 2009 | 382 | 0.320 |
Why?
|
| Insurance, Dental | 1 | 2010 | 4 | 0.320 |
Why?
|
| Healthcare Disparities | 5 | 2016 | 213 | 0.310 |
Why?
|
| Referral and Consultation | 1 | 2011 | 147 | 0.300 |
Why?
|
| Patient-Centered Care | 1 | 2011 | 185 | 0.300 |
Why?
|
| Anemia | 1 | 2010 | 34 | 0.300 |
Why?
|
| Quality of Health Care | 9 | 2011 | 249 | 0.300 |
Why?
|
| Office Visits | 1 | 2010 | 78 | 0.300 |
Why?
|
| Medicare | 3 | 2015 | 188 | 0.300 |
Why?
|
| Genetic Variation | 2 | 2015 | 67 | 0.290 |
Why?
|
| Asian Americans | 6 | 2012 | 146 | 0.290 |
Why?
|
| Health Care Surveys | 8 | 2013 | 201 | 0.290 |
Why?
|
| Hypolipidemic Agents | 5 | 2015 | 38 | 0.280 |
Why?
|
| Alcohol Drinking | 5 | 2008 | 298 | 0.270 |
Why?
|
| Myocardial Infarction | 4 | 2015 | 215 | 0.270 |
Why?
|
| Electronic Mail | 2 | 2019 | 52 | 0.270 |
Why?
|
| Physicians | 2 | 2020 | 114 | 0.260 |
Why?
|
| Premature Birth | 2 | 2020 | 133 | 0.260 |
Why?
|
| Polypharmacy | 3 | 2026 | 16 | 0.260 |
Why?
|
| Pregnancy Outcome | 2 | 2014 | 160 | 0.260 |
Why?
|
| Cost of Illness | 2 | 2007 | 90 | 0.250 |
Why?
|
| Drugs, Generic | 1 | 2026 | 6 | 0.250 |
Why?
|
| Asian Continental Ancestry Group | 4 | 2016 | 69 | 0.240 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2006 | 41 | 0.240 |
Why?
|
| Body Size | 1 | 2006 | 27 | 0.240 |
Why?
|
| Risk | 4 | 2013 | 453 | 0.240 |
Why?
|
| Carotid Artery Diseases | 2 | 2003 | 9 | 0.230 |
Why?
|
| Drug Monitoring | 1 | 2026 | 23 | 0.230 |
Why?
|
| Surveys and Questionnaires | 9 | 2018 | 1204 | 0.230 |
Why?
|
| Pharmacists | 1 | 2026 | 53 | 0.230 |
Why?
|
| Prevalence | 9 | 2020 | 785 | 0.230 |
Why?
|
| Deprescriptions | 1 | 2025 | 12 | 0.220 |
Why?
|
| Confidence Intervals | 3 | 2021 | 207 | 0.220 |
Why?
|
| Survival Rate | 7 | 2015 | 247 | 0.220 |
Why?
|
| Health Personnel | 4 | 2020 | 132 | 0.220 |
Why?
|
| Poisson Distribution | 3 | 2015 | 84 | 0.220 |
Why?
|
| Medicaid | 2 | 2017 | 189 | 0.220 |
Why?
|
| Cost-Benefit Analysis | 3 | 2015 | 229 | 0.210 |
Why?
|
| Renal Dialysis | 2 | 2004 | 57 | 0.210 |
Why?
|
| Insurance Coverage | 3 | 2017 | 102 | 0.210 |
Why?
|
| Sex Factors | 7 | 2017 | 560 | 0.210 |
Why?
|
| Linguistics | 2 | 2021 | 4 | 0.210 |
Why?
|
| Linear Models | 6 | 2013 | 187 | 0.210 |
Why?
|
| Data Collection | 4 | 2014 | 223 | 0.210 |
Why?
|
| Quality Indicators, Health Care | 4 | 2014 | 126 | 0.210 |
Why?
|
| Perception | 3 | 2016 | 53 | 0.200 |
Why?
|
| Cognitive Dysfunction | 2 | 2022 | 61 | 0.200 |
Why?
|
| Tuberculosis | 1 | 2004 | 23 | 0.200 |
Why?
|
| Pharmacies | 2 | 2015 | 9 | 0.200 |
Why?
|
| Oceanic Ancestry Group | 3 | 2012 | 30 | 0.200 |
Why?
|
| Disease Management | 3 | 2015 | 106 | 0.190 |
Why?
|
| Health Knowledge, Attitudes, Practice | 4 | 2014 | 352 | 0.190 |
Why?
|
| Hypertension | 8 | 2015 | 475 | 0.190 |
Why?
|
| Epidemiology | 1 | 2003 | 6 | 0.190 |
Why?
|
| Patient Satisfaction | 4 | 2011 | 186 | 0.190 |
Why?
|
| Natural Language Processing | 2 | 2020 | 60 | 0.190 |
Why?
|
| Prejudice | 3 | 2011 | 21 | 0.190 |
Why?
|
| Glucose Tolerance Test | 7 | 2004 | 108 | 0.190 |
Why?
|
| Life Tables | 1 | 2012 | 7 | 0.180 |
Why?
|
| Research Design | 5 | 2023 | 319 | 0.180 |
Why?
|
| Hyperlipidemias | 4 | 2011 | 43 | 0.180 |
Why?
|
| Preventive Health Services | 1 | 2003 | 142 | 0.180 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 410 | 0.180 |
Why?
|
| Abortion, Spontaneous | 1 | 2012 | 49 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2003 | 145 | 0.170 |
Why?
|
| Health Services Research | 3 | 2013 | 180 | 0.170 |
Why?
|
| Numbers Needed To Treat | 1 | 2021 | 2 | 0.170 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2011 | 35 | 0.170 |
Why?
|
| Selection Bias | 1 | 2021 | 16 | 0.170 |
Why?
|
| Motor Activity | 2 | 2013 | 196 | 0.170 |
Why?
|
| Diabetic Retinopathy | 2 | 2014 | 17 | 0.170 |
Why?
|
| Income | 5 | 2014 | 81 | 0.170 |
Why?
|
| Propensity Score | 1 | 2021 | 78 | 0.170 |
Why?
|
| Cerebrovascular Disorders | 2 | 2013 | 29 | 0.160 |
Why?
|
| Health Services Needs and Demand | 1 | 2021 | 84 | 0.160 |
Why?
|
| Pharmacy | 1 | 2020 | 12 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 317 | 0.160 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2020 | 6 | 0.160 |
Why?
|
| Cause of Death | 4 | 2015 | 171 | 0.150 |
Why?
|
| Philippines | 3 | 2015 | 25 | 0.150 |
Why?
|
| Withholding Treatment | 1 | 2019 | 26 | 0.150 |
Why?
|
| Sleep | 1 | 2020 | 54 | 0.150 |
Why?
|
| Genomic Imprinting | 1 | 1999 | 2 | 0.150 |
Why?
|
| Poverty | 3 | 2015 | 167 | 0.150 |
Why?
|
| Child Development | 1 | 2020 | 58 | 0.150 |
Why?
|
| Insurance Claim Review | 4 | 2015 | 48 | 0.140 |
Why?
|
| Models, Statistical | 3 | 2017 | 164 | 0.140 |
Why?
|
| Feeding Behavior | 2 | 2018 | 161 | 0.140 |
Why?
|
| Reindeer | 2 | 1996 | 2 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2015 | 319 | 0.140 |
Why?
|
| San Francisco | 2 | 2016 | 54 | 0.140 |
Why?
|
| Logistic Models | 6 | 2014 | 796 | 0.140 |
Why?
|
| Caregivers | 1 | 2019 | 132 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2011 | 305 | 0.130 |
Why?
|
| Dietary Fats | 2 | 2001 | 88 | 0.130 |
Why?
|
| Social Class | 2 | 2011 | 106 | 0.130 |
Why?
|
| Food | 2 | 2018 | 36 | 0.130 |
Why?
|
| Albuminuria | 3 | 2015 | 39 | 0.130 |
Why?
|
| Population Dynamics | 1 | 2017 | 7 | 0.130 |
Why?
|
| Reproducibility of Results | 6 | 2012 | 346 | 0.130 |
Why?
|
| Forecasting | 2 | 2015 | 67 | 0.130 |
Why?
|
| Medically Uninsured | 1 | 2017 | 43 | 0.130 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2017 | 16 | 0.130 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 35 | 0.130 |
Why?
|
| Police | 1 | 2016 | 1 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 103 | 0.120 |
Why?
|
| Longevity | 3 | 2022 | 14 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2017 | 64 | 0.120 |
Why?
|
| Influenza Vaccines | 1 | 2020 | 300 | 0.120 |
Why?
|
| Self Efficacy | 2 | 2014 | 68 | 0.120 |
Why?
|
| Influenza, Human | 1 | 2020 | 292 | 0.120 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2020 | 158 | 0.120 |
Why?
|
| Appetite | 1 | 1996 | 1 | 0.120 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 1996 | 1 | 0.120 |
Why?
|
| Nematode Infections | 1 | 1996 | 1 | 0.120 |
Why?
|
| Pregnancy | 4 | 2020 | 1555 | 0.120 |
Why?
|
| Analysis of Variance | 2 | 2015 | 120 | 0.120 |
Why?
|
| Disease Progression | 4 | 2016 | 252 | 0.120 |
Why?
|
| Medical Order Entry Systems | 1 | 2015 | 10 | 0.110 |
Why?
|
| Cholesterol, HDL | 1 | 2015 | 64 | 0.110 |
Why?
|
| Nutrition Surveys | 2 | 2018 | 56 | 0.110 |
Why?
|
| Fast Foods | 1 | 2015 | 12 | 0.110 |
Why?
|
| Mutation Rate | 1 | 2015 | 3 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 18 | 0.110 |
Why?
|
| Exome | 1 | 2015 | 14 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 3 | 0.110 |
Why?
|
| Safety-net Providers | 1 | 2015 | 52 | 0.110 |
Why?
|
| Spatial Analysis | 1 | 2014 | 11 | 0.110 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 44 | 0.110 |
Why?
|
| Remission Induction | 1 | 2014 | 22 | 0.110 |
Why?
|
| Drug Prescriptions | 2 | 2013 | 137 | 0.110 |
Why?
|
| Weight Gain | 1 | 2016 | 167 | 0.110 |
Why?
|
| Metabolic Syndrome | 2 | 2005 | 59 | 0.110 |
Why?
|
| Case-Control Studies | 5 | 2013 | 995 | 0.100 |
Why?
|
| Health Care Costs | 2 | 2006 | 192 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2012 | 261 | 0.100 |
Why?
|
| Health Resources | 1 | 2014 | 35 | 0.100 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2016 | 305 | 0.100 |
Why?
|
| Metformin | 2 | 2020 | 49 | 0.100 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2014 | 22 | 0.100 |
Why?
|
| Urinary Incontinence | 1 | 2013 | 7 | 0.100 |
Why?
|
| Terminology as Topic | 1 | 2013 | 14 | 0.100 |
Why?
|
| Models, Theoretical | 3 | 2025 | 66 | 0.100 |
Why?
|
| Apolipoproteins | 1 | 2013 | 2 | 0.100 |
Why?
|
| Lipoproteins | 1 | 2013 | 13 | 0.100 |
Why?
|
| Reference Values | 3 | 2008 | 78 | 0.100 |
Why?
|
| Prediabetic State | 2 | 2013 | 63 | 0.100 |
Why?
|
| Antiviral Agents | 1 | 2014 | 92 | 0.100 |
Why?
|
| Diptera | 1 | 1992 | 1 | 0.090 |
Why?
|
| Humidity | 1 | 1992 | 2 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 3 | 2014 | 76 | 0.090 |
Why?
|
| Psychometrics | 1 | 2013 | 114 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2013 | 569 | 0.090 |
Why?
|
| Bariatric Surgery | 1 | 2014 | 134 | 0.090 |
Why?
|
| Musculoskeletal Pain | 1 | 2012 | 26 | 0.090 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2003 | 91 | 0.090 |
Why?
|
| Medical Records | 3 | 2007 | 85 | 0.090 |
Why?
|
| Prognosis | 5 | 2016 | 568 | 0.090 |
Why?
|
| Death Certificates | 1 | 2011 | 16 | 0.090 |
Why?
|
| Discrimination (Psychology) | 1 | 2011 | 1 | 0.090 |
Why?
|
| Interpersonal Relations | 1 | 2011 | 38 | 0.090 |
Why?
|
| Sex Distribution | 4 | 2012 | 164 | 0.080 |
Why?
|
| Age Distribution | 4 | 2012 | 221 | 0.080 |
Why?
|
| Ambulatory Care Information Systems | 1 | 2011 | 3 | 0.080 |
Why?
|
| Databases, Factual | 3 | 2013 | 294 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2025 | 311 | 0.080 |
Why?
|
| Prescription Fees | 1 | 2010 | 4 | 0.080 |
Why?
|
| Cost Control | 1 | 2010 | 12 | 0.080 |
Why?
|
| Blood Pressure | 4 | 2016 | 278 | 0.080 |
Why?
|
| Patients | 1 | 2010 | 29 | 0.080 |
Why?
|
| Comprehension | 1 | 2010 | 19 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2009 | 155 | 0.080 |
Why?
|
| Hawaii | 2 | 2020 | 62 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2010 | 92 | 0.080 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 18 | 0.070 |
Why?
|
| Primary Prevention | 1 | 2010 | 60 | 0.070 |
Why?
|
| Accidental Falls | 1 | 2009 | 49 | 0.070 |
Why?
|
| Drug Therapy | 1 | 2009 | 16 | 0.070 |
Why?
|
| Patient Selection | 2 | 2008 | 175 | 0.070 |
Why?
|
| Predictive Value of Tests | 5 | 2012 | 325 | 0.070 |
Why?
|
| Body Weight | 2 | 2003 | 197 | 0.070 |
Why?
|
| Depressive Disorder, Major | 1 | 2009 | 95 | 0.070 |
Why?
|
| Exercise | 5 | 2016 | 513 | 0.070 |
Why?
|
| Infant | 2 | 2020 | 1212 | 0.070 |
Why?
|
| International Classification of Diseases | 3 | 2015 | 84 | 0.070 |
Why?
|
| Treatment Refusal | 1 | 2008 | 30 | 0.070 |
Why?
|
| Social Problems | 1 | 2007 | 4 | 0.070 |
Why?
|
| Drug Costs | 1 | 2007 | 32 | 0.070 |
Why?
|
| Torticollis | 1 | 2007 | 1 | 0.070 |
Why?
|
| Self Disclosure | 1 | 2007 | 16 | 0.070 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2007 | 18 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2007 | 58 | 0.060 |
Why?
|
| Walking | 1 | 2008 | 82 | 0.060 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2006 | 51 | 0.060 |
Why?
|
| Translational Medical Research | 3 | 2012 | 24 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2006 | 80 | 0.060 |
Why?
|
| Sex Characteristics | 3 | 2004 | 58 | 0.060 |
Why?
|
| Seasons | 1 | 2017 | 114 | 0.060 |
Why?
|
| Medicare Part D | 1 | 2026 | 17 | 0.060 |
Why?
|
| Monte Carlo Method | 1 | 2006 | 10 | 0.060 |
Why?
|
| Stroke | 2 | 2015 | 297 | 0.060 |
Why?
|
| State Medicine | 1 | 2006 | 4 | 0.060 |
Why?
|
| Markov Chains | 1 | 2006 | 19 | 0.060 |
Why?
|
| United Kingdom | 1 | 2006 | 24 | 0.060 |
Why?
|
| Reagent Strips | 1 | 2006 | 1 | 0.060 |
Why?
|
| Mass Screening | 2 | 2014 | 670 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 28 | 0.060 |
Why?
|
| Minority Groups | 2 | 2011 | 99 | 0.060 |
Why?
|
| PPAR gamma | 1 | 2005 | 9 | 0.060 |
Why?
|
| Child | 2 | 2020 | 2433 | 0.060 |
Why?
|
| Age of Onset | 2 | 2020 | 66 | 0.060 |
Why?
|
| Abdomen | 1 | 2005 | 19 | 0.060 |
Why?
|
| Pedigree | 1 | 2005 | 27 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2005 | 21 | 0.050 |
Why?
|
| Demography | 3 | 2013 | 89 | 0.050 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2025 | 63 | 0.050 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2004 | 8 | 0.050 |
Why?
|
| Self-Management | 1 | 2024 | 25 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2004 | 24 | 0.050 |
Why?
|
| Animals | 2 | 1996 | 237 | 0.050 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2003 | 5 | 0.050 |
Why?
|
| Lipoproteins, LDL | 1 | 2003 | 12 | 0.050 |
Why?
|
| Genetics, Population | 1 | 2003 | 8 | 0.050 |
Why?
|
| Health Education | 1 | 2003 | 79 | 0.050 |
Why?
|
| Progestins | 1 | 2003 | 24 | 0.050 |
Why?
|
| Activities of Daily Living | 2 | 2013 | 71 | 0.050 |
Why?
|
| Estrogens | 1 | 2003 | 55 | 0.050 |
Why?
|
| Survival Analysis | 2 | 2013 | 191 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2014 | 88 | 0.050 |
Why?
|
| Databases, Bibliographic | 1 | 2012 | 6 | 0.050 |
Why?
|
| Public Health | 1 | 2003 | 80 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2004 | 205 | 0.050 |
Why?
|
| Fibrinogen | 1 | 2001 | 11 | 0.040 |
Why?
|
| Alcoholics Anonymous | 1 | 2011 | 6 | 0.040 |
Why?
|
| Gestational Age | 1 | 2012 | 118 | 0.040 |
Why?
|
| Texas | 2 | 2003 | 40 | 0.040 |
Why?
|
| Adipose Tissue | 1 | 2001 | 63 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2001 | 52 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2014 | 160 | 0.040 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2001 | 68 | 0.040 |
Why?
|
| Colorado | 2 | 2003 | 171 | 0.040 |
Why?
|
| Writing | 1 | 2020 | 12 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2001 | 71 | 0.040 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 374 | 0.040 |
Why?
|
| Attitude of Health Personnel | 2 | 2013 | 197 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 60 | 0.040 |
Why?
|
| Executive Function | 1 | 2019 | 29 | 0.040 |
Why?
|
| Proxy | 1 | 2019 | 4 | 0.040 |
Why?
|
| Vaccines, Inactivated | 1 | 2020 | 73 | 0.040 |
Why?
|
| Cognition Disorders | 1 | 2019 | 30 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2004 | 1430 | 0.040 |
Why?
|
| Nuclear Family | 1 | 1999 | 7 | 0.040 |
Why?
|
| Confidentiality | 1 | 2019 | 25 | 0.040 |
Why?
|
| Fathers | 1 | 1999 | 9 | 0.040 |
Why?
|
| Focus Groups | 1 | 2019 | 140 | 0.040 |
Why?
|
| Mothers | 1 | 1999 | 104 | 0.030 |
Why?
|
| Geography | 1 | 2018 | 39 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2018 | 58 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2019 | 288 | 0.030 |
Why?
|
| Biomarkers | 2 | 2013 | 284 | 0.030 |
Why?
|
| Acitretin | 1 | 1997 | 1 | 0.030 |
Why?
|
| Psoriasis | 1 | 1997 | 9 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2020 | 828 | 0.030 |
Why?
|
| Software | 1 | 1997 | 18 | 0.030 |
Why?
|
| Professional Competence | 1 | 2016 | 15 | 0.030 |
Why?
|
| Computer Simulation | 1 | 1997 | 84 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 1 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 3 | 0.030 |
Why?
|
| Introns | 1 | 2016 | 6 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 26 | 0.030 |
Why?
|
| Islets of Langerhans | 1 | 2016 | 11 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2016 | 15 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 29 | 0.030 |
Why?
|
| Mortality | 1 | 1997 | 116 | 0.030 |
Why?
|
| Unemployment | 1 | 2016 | 12 | 0.030 |
Why?
|
| Abomasum | 1 | 1996 | 1 | 0.030 |
Why?
|
| Antinematodal Agents | 1 | 1996 | 1 | 0.030 |
Why?
|
| Cestoda | 1 | 1996 | 1 | 0.030 |
Why?
|
| Coccidia | 1 | 1996 | 1 | 0.030 |
Why?
|
| Ivermectin | 1 | 1996 | 1 | 0.030 |
Why?
|
| Nematoda | 1 | 1996 | 1 | 0.030 |
Why?
|
| Parasite Egg Count | 1 | 1996 | 1 | 0.030 |
Why?
|
| Animals, Domestic | 1 | 1996 | 4 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 110 | 0.030 |
Why?
|
| Diet | 3 | 2006 | 349 | 0.030 |
Why?
|
| Urban Population | 1 | 2016 | 105 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 56 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 209 | 0.030 |
Why?
|
| Feces | 1 | 1996 | 90 | 0.030 |
Why?
|
| Epidemiological Monitoring | 1 | 2015 | 21 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 17 | 0.030 |
Why?
|
| Vitamin A Deficiency | 1 | 1995 | 3 | 0.030 |
Why?
|
| Glucose-6-Phosphatase | 1 | 2015 | 2 | 0.030 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2015 | 3 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 23 | 0.030 |
Why?
|
| Models, Biological | 2 | 2006 | 26 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 57 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 41 | 0.030 |
Why?
|
| Mathematical Concepts | 1 | 2014 | 3 | 0.030 |
Why?
|
| Self Administration | 1 | 2014 | 7 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1995 | 58 | 0.030 |
Why?
|
| Maternal Age | 1 | 2014 | 73 | 0.030 |
Why?
|
| Indians, North American | 1 | 2013 | 44 | 0.020 |
Why?
|
| Diabetic Foot | 1 | 2013 | 3 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2014 | 100 | 0.020 |
Why?
|
| Inflammation | 2 | 2005 | 56 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 110 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 129 | 0.020 |
Why?
|
| Larva | 1 | 1992 | 1 | 0.020 |
Why?
|
| Oviposition | 1 | 1992 | 1 | 0.020 |
Why?
|
| Ovum | 1 | 1992 | 2 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2012 | 25 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2012 | 21 | 0.020 |
Why?
|
| New Jersey | 1 | 2012 | 4 | 0.020 |
Why?
|
| Indiana | 1 | 2012 | 3 | 0.020 |
Why?
|
| Employment | 1 | 2012 | 38 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2011 | 51 | 0.020 |
Why?
|
| Far East | 1 | 2011 | 4 | 0.020 |
Why?
|
| HIV Infections | 1 | 1997 | 708 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2010 | 12 | 0.020 |
Why?
|
| Mobility Limitation | 1 | 2010 | 15 | 0.020 |
Why?
|
| Choice Behavior | 1 | 2010 | 44 | 0.020 |
Why?
|
| Pain | 1 | 2010 | 65 | 0.020 |
Why?
|
| Diet, Diabetic | 1 | 2010 | 7 | 0.020 |
Why?
|
| Attitude to Health | 1 | 2011 | 142 | 0.020 |
Why?
|
| Energy Metabolism | 2 | 2001 | 47 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 94 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2009 | 75 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2009 | 305 | 0.020 |
Why?
|
| Medical Audit | 1 | 2008 | 31 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 66 | 0.020 |
Why?
|
| Drug Utilization Review | 1 | 2007 | 21 | 0.020 |
Why?
|
| Anxiety | 1 | 2009 | 154 | 0.020 |
Why?
|
| Feedback | 1 | 2006 | 22 | 0.020 |
Why?
|
| Information Systems | 1 | 2006 | 15 | 0.020 |
Why?
|
| Reminder Systems | 1 | 2006 | 76 | 0.010 |
Why?
|
| Linkage Disequilibrium | 1 | 2005 | 23 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2005 | 15 | 0.010 |
Why?
|
| Haplotypes | 1 | 2005 | 29 | 0.010 |
Why?
|
| Alleles | 1 | 2005 | 59 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 198 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 2003 | 21 | 0.010 |
Why?
|
| Biology | 1 | 2003 | 1 | 0.010 |
Why?
|
| Sociology | 1 | 2003 | 2 | 0.010 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2003 | 9 | 0.010 |
Why?
|
| Anthropometry | 1 | 2003 | 54 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2003 | 32 | 0.010 |
Why?
|
| Culture | 1 | 2003 | 28 | 0.010 |
Why?
|
| Energy Intake | 1 | 2003 | 98 | 0.010 |
Why?
|
| Genomics | 1 | 2003 | 54 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 104 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 2002 | 34 | 0.010 |
Why?
|
| Creatinine | 1 | 2002 | 67 | 0.010 |
Why?
|
| Postmenopause | 1 | 2003 | 243 | 0.010 |
Why?
|
| Carotid Arteries | 1 | 2001 | 8 | 0.010 |
Why?
|
| Infection | 1 | 2001 | 17 | 0.010 |
Why?
|
| Body Composition | 1 | 2001 | 90 | 0.010 |
Why?
|
| Leisure Activities | 1 | 2001 | 29 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1997 | 210 | 0.010 |
Why?
|
| New York City | 1 | 1995 | 22 | 0.010 |
Why?
|
| Vitamin A | 1 | 1995 | 12 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1995 | 32 | 0.010 |
Why?
|
| Eating | 1 | 1995 | 35 | 0.010 |
Why?
|